Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio
ConclusionNLR ≥ 2.5 at CRPC diagnosis is associated with a lower risk for CSS. Patients with NLR < 2.5 should primarily be offered docetaxel considering the survival benefit of docetaxel-to-ARAT agent sequencing.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Prostate Cancer | Radiography | Taxotere | Urology & Nephrology